Lei Shi

This inventor holds 20 USPTO granted patents and 10 published patent applications, plus 9 CIPO patents and 8 EPO patents, primarily in Wound Healing Technologies. Top assignees: Smith + Nephew, Smith & Nephew, Inc., Amgen Inc.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lei Shi. Retrieved from https://idiyas.com/inventor/lei-shi-avxcz1iq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 10)

% Patents Active = 95.0

CIPO Patents = 9 (Patent Applications = 36)

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 10(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2010)
Memphis, TN (US) (2023)
Mansfield, TX (US) (2015 - 2024)

Company Filing History:

Smith & Nephew Orthopaedics Ag

patents

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Wound Healing

Antibacterial Agents

Gel-Forming Films

Biofilms

Thermolysin

Clostridium Histolyticum

Enzymatic Activity

Topical Delivery

Seaprose

Active Ingredients

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697374 - Use of clostridium histolyticum protease mixture in promoting wound healing (2026-08-04),

2. 12588675 - Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms (2026-03-31),

3. 12377055 - Dissolvable gel-forming film for delivery of active agents (2025-08-05),

4. 12023412 - Dissolvable gel-forming film for delivery of active agents (2024-07-02),

5. 12016907 - Stable thermolysin hydrogel (2024-06-25),

6. 11957698 - Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces (2024-04-16),

7. 11938173 - Use ofprotease mixture in promoting wound healing (2024-03-26),

8. 11641856 - Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms (2023-05-09),

9. 11628207 - Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces (2023-04-18),

10. 11452698 - Dissolvable gel-forming film for delivery of active agents (2022-09-27),

11. 11446364 - Stable thermolysin hydrogel (2022-09-20),

12. 11413300 - Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces (2022-08-16),

13. 11197476 - Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms (2021-12-14),

14. 11096992 - Use of seaprose to remove bacterial biofilm (2021-08-24),

15. 10556037 - Enzymatic wound debriding compositions with enhanced enzymatic activity (2020-02-11),

Title: Lei Shi: Innovator in Tumor Necrosis Factor Receptor Compositions

Introduction

Lei Shi, an inventor based in Thousand Oaks, California, has made significant contributions to medical science through his innovative work. With one patented invention to his name, he is recognized for his advancements in the field of biopharmaceuticals, particularly in developing improved compositions for tumor necrosis factor receptors.

Latest Patents

Lei Shi's most notable patent is focused on "Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing." This invention provides enhanced formulations of PEGsTNF-R1 that not only achieve useful higher concentrations but also exhibit decreased viscosity (less than 400 cP) and improved stability. These advancements may lead to more effective treatment options for various diseases.

Career Highlights

Currently, Lei Shi is associated with Amgen Inc., a leading biotechnology company committed to developing innovative therapies. His work at Amgen underscores his dedication to improving patient outcomes through research and development in biomedicine.

Collaborations

Throughout his career, Lei Shi has collaborated with professionals such as Bruce A. Kerwin and Byeong Seon Chang. These collaborations reflect a synergistic approach to research, enhancing the quality and impact of their collective work in the biotechnology field.

Conclusion

In summary, Lei Shi's contributions to the development of pegylated soluble tumor necrosis factor receptor compositions represent a meaningful step forward in biopharmaceutical innovations. His work at Amgen Inc. and collaborations with notable colleagues underscore his role in advancing medical science, ultimately aiming to provide better therapeutic solutions for patients.

Profile summary based on public USPTO records.